1239233-87-4

Basic information

• Product Name: 2-[3-Carboxy-4-(2-Methylpropoxy)phenyl]-4-Methyl-5-thiazolecarboxylic Acid
• Synonyms: Febuxostat Dicarboxylic Acid Impurity;2-(3-carboxy-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid;2-[3-Carboxy-4-(2-Methylpropoxy)phenyl]-4-Methyl-5-thiazolecarboxylic Acid
• CAS NO: 1239233-87-4
• Molecular Formula: C₁₆H₁₇NO₅S
• Molecular Weight: 335.37488
• Product Categories: Aromatics, Heterocycles, Impurities, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 1239233-87-4.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 568.9±60.0 °C(Predicted)
• Appearance: /
• Density: 1.327±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 1.21±0.37(Predicted)
• CAS DataBase Reference: 2-[3-Carboxy-4-(2-Methylpropoxy)phenyl]-4-Methyl-5-thiazolecarboxylic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-[3-Carboxy-4-(2-Methylpropoxy)phenyl]-4-Methyl-5-thiazolecarboxylic Acid(1239233-87-4)
• EPA Substance Registry System: 2-[3-Carboxy-4-(2-Methylpropoxy)phenyl]-4-Methyl-5-thiazolecarboxylic Acid(1239233-87-4)

Safety Data

• Hazardous Substances Data: 1239233-87-4(Hazardous Substances Data)

Usage

Uses

2-[3-Carboxy-4-(2-methylpropoxy)phenyl]-4-methyl-5-thiazolecarboxylic Acid is an impurity of Febuxostat (F229000), an xanthine oxidase/ xanthine dehydrogenase inhibitor used for the treatment of hyperuricemia and chronic gout.

Upstream product

• 144060-53-7 febuxostat 
• 160844-75-7 2-(3-cyano-4-isobutyloxyphenyl)-4-methylthiazole-5-carboxylic acid ethyl ester 

Downstream Products

• 144060-53-7 febuxostat 

Relevant articles and documents

TREATMENT ACTIVITY AND NURSING VALUES OF A HETEROCYCLIC COMPOUND COMBINED WITH ASPIRIN ON TRAUMATIC ARTHRITIS

Abstract: Heterocyclic compound 2-(3-(ethoxycarbonyl)-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid (1) designed using 2-(3-cyano-4-isobutoxyphenyl)-4-methylthiazole-5-carboxylic acid (2, Febuxostat) as a starting material is successfully prepared via a multistage synthesis route and finally characterized by IR,1H NMR, and single crystal X-ray diffraction. Its treatment activity combined with aspirin on traumatic arthritis is evaluated along with the related mechanism. Firstly, the ELISA detection is conducted to determine the inflammatory response released into the joint cavity secretion. Additionally, real time RT-PCR is measured and the activation levels of NF-κb are determined after the indicated treatment. [Figure not available: see fulltext.]